p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer

Anticancer Research

Volumn 23, Issue 2 B, 2003, Pages 1207-1212

  Bergqvist, Michael ^a   Brattström, Daniel ^a   Gullbo, Joachim ^a   Hesselius, Patrik ^a   Brodin, Ola ^b   Wagenius, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cDNA; Chemosensitivity; Exon; Lung cancer; p53; Radiosensitivity

Indexed keywords

CISPLATIN; CLADRIBINE; COMPLEMENTARY DNA; CYTARABINE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; MELPHALAN; PROTEIN P53; TOPOTECAN; VINBLASTINE;

ARTICLE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SENSITIVITY; EXON; GENE DELETION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MISSENSE MUTATION; PRIORITY JOURNAL; RADIOSENSITIVITY;

EID: 0038577103     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Olive PL and Banath JP: Radiation-induced DNA double-strand breaks produced in histone-depleted tumor cell nuclei measured using the neutral comet assay. Radiat Res 142: 144-152, 1995.
2. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
3. Komiya T, Hirashima T and Kawase I: Clinical significance of p53 in non-small-cell lung cancer. Oncol Rep 6: 19-28, 1999.
4. Mack DH, Vartikar J, Pipas JM and Laimins LA: Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363: 281-283, 1993.
5. D'Amico D, Carbone D, Mitsudomi T et al: high frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7: 339-346, 1992.
6. Chiba I, Takahashi T, Nau MM et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 5: 1603-1610, 1990.
7. Berg C, Hedrum A, Holmberg A et al: Direct solid-phase sequence analysis of the human p53 gene by use of nultiplex polymerase chain reaction and alpha-thiotriphosphate nucleotides. Clin Chem 41: 1461-1466, 1995.
8. Larsson R, Kristensen J, Sandberg C and Nygren P: Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185, 1992.
9. Brodin O, Arnberg H, Bergh J and Nilsson S: Increased radioresistance of an in vitro transformed human small cell lung cancer cell line. Lung Cancer 12: 183-198, 1995.
10. Mitsudomi T, Steinberg SM, Nau MM et al: p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180, 1992.
11. Burns TF and El-Deiry WS: The p53 pathway and apoptosis. J Cell Physiol 181: 231-239, 1999.
12. Waldman T, Kinzler KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190, 1995.
13. Matsuzoe D, Hideshima T, Kimura A et al: p53 mutations predict non-small cell lung carcinoma response to radiotherapy. Cancer Lett 135: 189-194, 1999.
14. McIlwrath AJ, Vasey PA, Ross GM and Brown R: Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722, 1994.
15. Siles E, Villalobos M, Valenzuela MT et al: Relationship between p53 status and radiosensitivity in human tumour cell lines. Br J Cancer 73: 581-588, 1996.
16. Bergh J: Quo vadis oncological therapies? The need for a better use of prognostic and predictive factors in clinical oncology- a review focusing on p53. Review Series 4: 2-23, 1998.
17. Perdomo JA, Naomoto Y, Haisa M et al: In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer. J Cancer Res Clin Oncol 124: 10-18, 1998.
18. Ruch V, Klimstra D, Venkatraman E et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038-5042, 1995.
19. kandioler-Eckersberger D, Kappel S, Mittlbock M et al: The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Sug 117: 774-750, 1999.
20. Brattstrom D, Bergqvist M, Lamberg K et al: Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med Oncol 15: 255-261, 1998.
21. Carulli G and Petrini M: Multidrug resistance: focus in hematology. Haematologica 75: 363-374, 1990.
22. Galimberti S, Marchetti A, Buttitta F et al: Multidrug resistance related genes and p53 expression in human non-small cell lung cancer. Anticancer Res 18: 2973-2976, 1998.
23. Brodin O: U-1690 an its corresponding SF 2 value. Manuscript in preparation.
24. Brodin O, Lennartsson L and Nilsson S: Single-dose and fractionated irradiation of four human lung cancer cell lines in vitro. Acta Oncol 30: 967-974, 1991.
25. Morstyn G, Russo A, Carney DN et al: Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines. J Natl Cancer Inst 73: 801-807, 1984.
26. Brachman DG, Beckett M, Graves D et al: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 53: 3667-3669, 1993.
27. Huang H, Li CY and Little JB: Abrogation of p53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation. Int J Radiat Biol 70: 151-160, 1996.
28. Jung M, Noratio V and Dritschilo A: Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 52: 6390-6393, 1992.
29. Mallya SM and Sikpi MO: Requirement for p53 in ionizing-radiation-inhibition of double-strand-break rejoining by human lymphoblasts. Mutat Res 434: 119-132, 1999.
30. Zaffaroni N, Benini E and Gornati D: Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells 13: 77-85, 1995.
31. Servomaa K, Kiuru A and Grenman R: p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif 29: 219-230, 1996.
32. Pekkola-Heino K, Servomaa K and Kiuru A: Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma. Acta Otolaryngol 116: 341-344, 1996.